Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope your weekend was a blissful one. Today, we talk about AbbVie’s outsize marketing spend, see how GLP-1s are impacting cancer rates, and more.
The need-to-know this morning
- Eli Lilly said it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease. Lilly will pay about $3.2 billion to buy the Waltham, Mass.-based company. That translates to $57 per share, a premium of roughly 79% from Morphic’s Friday closing price.
- Ideaya Biosciences reported results from a mid-stage study showing a 39% tumor response rate for its experimental cancer drug IDE397 in patients with bladder and lung cancer with an MTAP deletion.
- HilleVax said its experimental vaccine against the norovirus failed to reduce severe gastrointestinal events compared to a placebo in infants enrolled in a mid-stage clinical trial. The company intends to discontinue development of the vaccine, called HIL-214, in infants but may explore further development in adults.
AbbVie dramatically outspent rivals in drug promotion
AbbVie spent an eye-popping $145.7 million last year on marketing to health care providers, a STAT analysis of government data shows. This hefty expenditure, the highest of any pharma company since 2017, includes payments for consulting, speaking fees, travel, and meals for doctors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect